企業ニュース
- すべて
- Corporate News
- Events & Exhibitions
9月 17, 2021
Oasmia and FarmaMondo sign an agreement to commercialize Paclical® in Russia & CIS
9月 10, 2021
Mirum pharmaceuticals and FarmaMondo Group enter into an exclusive commercialization agreement for Russia and CIS region
7月 26, 2021
Ideogen AG and FarmaMondo enter into a managed access program agreement to allow Fotolyn, Beleodaq and Marqibo distribution in Russia, CIS market and Baltics
12月 27, 2020
Sarepta Therapeutics and FarmaMondo announce an agreement to exclusively manage access of eteplirsen and golodirsen in Russia
11月 10, 2020
Dompe’ farmaceutici and the FarmaMondo Group: exclusive agreement to distribute oxervate™ in Russia and other CIS countries
6月 1, 2020
FarmaMondo to exclusively manage access to Metreleptin (Myalept®) by Amryt Pharma for patients with lipodystrophy in CIS (excluding Russia)
4月 14, 2020
EUSA and FarmaMondo Group establishes an Emergency Managed Access Program to allow Healthcare Providers to access Siltuximab (Sylvant©) for off label treatment of acute patients of COVID-19
10月 2, 2019
FarmaMondo to exclusively Manage Access to Lomitapide (Lojuxta®) for the Swiss and CIS markets
6月 1, 2019
FarmaMondo to exclusively manage access of Qarziba® (Dinutuximab Beta) by EUSA Pharma for patients with High Risk Neuroblastoma in LATAM and APAC regions
5月 30, 2019
FarmaMondo to manage access to Carmustine Obvius for the Italian market
1月 2, 2019
FarmaMondo upgrades its presence in Mexico by establishing a local legal entity
10月 15, 2018
FarmaMondo Nordics receives GMP license from the Danish Medicines Agency
8月 20, 2018
FarmaMondo to manage access to Asparaginase (Spectrila® by Medac Pharma) for patients with acute lymphoblastic leukemia in Russia and CIS region
4月 28, 2018
Merck’s Keytruda tops chemotherapy for non-small cell lung cancer treatment
4月 25, 2018
FDA extends use of Tagrisso to metastatic non-small-cell lung cancer
3月 15, 2018
FarmaMondo appointed by Amomed Pharma to exclusively Manage Access for Argipressin (Empressin®) for Russia and CIS region
1月 1, 2018
FarmaMondo establishes presence in south EU markets to provide direct to hospital service around supply of unlicensed medicines
11月 17, 2017
CIS Medical Workshop around high risk Neuroblastoma management
11月 1, 2017
FarmaMondo establishes presence in Mexico to provide direct to hospital service around supply of unlicensed medicines
10月 17, 2017
FarmaMondo to manage access to Dinutuximab beta EUSA for patients with Neuroblastoma
10月 17, 2017
FarmaMondo to manage access to Qarziba® (Dinutuximab Beta) by EUSA Pharma) for patients with High Risk Neuroblastoma in Russia and CIS region
10月 1, 2016
FarmaMondo at Early Access Programmes Conference in London
9月 7, 2016
FarmaMondo appointed by Ideogen Pharma to Manage Access for Carmustine (Bicnu®) for Swiss market
3月 31, 2015
FarmaMondo appointed by Rev Pharma to exclusively Manage Access for Curefini® outside the United States
3月 10, 2015
FARMAMONDO honored as “Top trustworthy Swiss companies” by Dun & Bradstreet
9月 1, 2014
FarmaMondo re-position its Swiss retail unit to adapt to Group strategy
8月 15, 2013
FarmaMondo establishes presence in Argentina to provide direct to hospital service around supply of unlicensed medicines
7月 1, 2013
FarmaMondo appointed by Orion Pharma to Manage Access for levosimendan IV (Simdax®) for Swiss market
1月 5, 2013
